Stock Upgrades Today Highlight Top Picks

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  22 Dec 2025
 

•   AMD  
   
  +0.28%
•   BSX  
   
  +0.12%
•   CCL  
   
  +0.03%
•   CDNS  
   
  +0.22%
•   CMI  
   
  -0.32%

$AMD BofA maintains a Buy rating on AMD, viewing 2026 as the midpoint of a decade-long AI infrastructure cycle. The firm sees the chip portfolio positioned to benefit from expanding AI adoption across cloud computing and data centers. Investors looking at long-term tech growth could find AMD combination of CPU and GPU leadership compelling.

$BSX Boston Scientific continues to attract attention as a top healthcare AI stock. TD Cowen reaffirmed its Buy rating and named it their Best Idea for 2026 with a $115 price target. The firm cites strong product innovation and AI-driven medical devices as key drivers, positioning the company to capitalize on emerging trends in minimally invasive treatments.

$CCL Carnival cruised past pricing concerns with a strong quarter, prompting an upgrade to Buy and a price target of $34. Adjusted EPS beat estimates, and revenue hit a fourth-quarter record of $6.33 billion. Investors may see value in CCL ability to grow cash flow and sustain demand amid evolving travel trends.

$CDNS Needham reiterated its Buy rating on Cadence Design Systems, projecting a 24% upside. The firm highlights CDNS critical role in semiconductor design software and its positioning to benefit from the continued demand for advanced chips, making it an attractive pick for tech-focused traders.

$CMI Cummins caught analyst attention with upgrades reflecting confidence in the industrial and engine business. The firm sees upside in both short-term earnings and long-term positioning as global energy and transportation trends favor efficient engine technologies.

$CVGI Nomura sees Ashok Leyland as a key beneficiary of the commercial vehicle upcycle, raising the target to Rs 196. The brokerage also initiated coverage on Tata Motors CV with a 22% upside, highlighting how both companies stand to gain from improving demand and strategic growth, making the Indian CV market a compelling story.

$CYTK Cytokinetics retains strong Buy ratings from both Needham and HC Wainwright, with analysts projecting roughly 33% upside. Investors focused on biotech and therapeutic innovations may see CYTK as a promising candidate for near-term gains amid ongoing clinical developments.

$GNSS Ascendiant Capital maintains its Buy rating on Genasys, forecasting a massive 133% upside. The stock could appeal to growth-focused investors looking for companies with scalable tech solutions in communications and security systems.

$HOOD Groww shares surged over 20% after Jefferies initiated coverage with a Buy rating. The brokerage points to Robinhood-like strategies and expected 35% earnings growth from new products and margin expansion, making HOOD a high-profile fintech opportunity.

$ISRG Intuitive Surgical retains its Buy rating from Baird following new FDA clearances. The company continues to be recognized as a leading healthcare AI stock, and investors may see upside potential as surgical robotics adoption expands.

$IVVD BTIG initiated coverage on Invivyd with a Buy rating, projecting a staggering 225% upside. This biotech newcomer could be attractive to speculative investors seeking early exposure to potentially transformative therapies.

$KLAC KLA upgrade to Buy by Jefferies emphasizes AI-driven growth in semiconductor equipment. With a new price target of $1500, the firm notes that the run may just be starting, appealing to traders focused on semiconductor and AI hardware momentum.

$LEU Needham reiterated its Buy rating on Centrus Energy, forecasting a modest 7.29% upside. While smaller, the company could attract investors seeking exposure to the nuclear energy sector with potential for steady, conservative growth.

$LLY Eli Lilly remains a Buy with BofA citing 2027 earnings that should fully reflect the value of new obesity drug launches. The stock combines biotech innovation with established pharmaceutical strength, providing a balanced investment case.

$NFLX Jefferies affirmed Buy on Netflix, noting potential benefits from the Warner Bros. Discovery acquisition. Investors might see upside as synergies from content integration and subscriber growth play out in the near term.

$OLED Needham reaffirmed its Buy on Universal Display, projecting nearly 48% upside. OLED materials and display technology remain in high demand across consumer electronics, positioning it as a strong growth play.

$OTLK Ascendiant Capital maintained its Buy rating on Outlook Therapeutics, highlighting a 382% upside potential. This speculative biotech offers aggressive upside for traders seeking high-risk, high-reward opportunities.

$SGRY Surgery Partners retains its Buy from Mizuho with a 21% upside. Mid-cap healthcare investors may find value in its growing market share and exposure to elective surgical procedures.

$SRFM Surf Air Mobility upgraded to Buy, reflecting optimism around the company’s innovative mobility solutions. With potential growth in electric and hybrid air transportation, SRFM could be a compelling speculative investment.

$SYK Stryker maintains its Buy rating despite a reduced-price target from Citi. Leadership changes and sector-wide adjustments are part of the story, but investors focused on healthcare AI and surgical solutions may still see long-term potential.

$TJX UBS maintains a Buy rating on TJX, citing market share gains and strong retail positioning. Investors may see the stock as a steady performer in consumer discretionary with potential for earnings stability.

$VEEV Veeva continues to earn a Buy from Stifel, despite CRM customer migrations. The strong presence in life sciences and SaaS offerings keeps it attractive for investors seeking exposure to healthcare technology.

$VKTX Viking Therapeutics is up nearly 190% in upside potential according to H.C. Wainwright. Mid-cap healthcare investors may find the stock compelling given its pipeline and growth trajectory.

$WYFI WhiteFiber maintains its Buy rating with a forecasted 120% upside. Investors seeking high-growth opportunities in fiber-optic and communications infrastructure may find WYFI appealing.

View All Headlines